(MRSN) – Momentum Movers
-
Mersana Therapeutics (MRSN) falls 47% after announcing UPLIFT clinical trial did not meet its primary endpoint
-
Mersana Therapeutics (MRSN) Plunges 48% Following Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
Back to MRSN Stock Lookup